Hinyokika Kiyo. 2008 Jun;54(6):435-45.

[Assessment of clinical usefulness of Eviprostat for benign prostatic hyperplasia--comparison of Eviprostat tablet with a formulation containing two-times more active ingredients].

[Article in Japanese]

Tamaki M1, Nakashima M, Nishiyama R, Ikeda H, Hiura M, Kanaoka T, Nakano T, Hayashi T, Ogawa O.

• 1Department of Urology, Japanese Red Cross Society Wakayama Medical Center.

Abstract

We compared the usefulness of Eviprostat tablet, a therapeutic agent for benign prostatic hyperplasia (BPH), and EVI-F tablet, a new formulation of Eviprostat containing two times more active ingredients :

• Chimaphila umbellata extract,
• Populus tremula extract,
• Pulsatilla pratensis extract,
• Equisetum arvense extract and
• purified wheat germ oil

and consequently designed to reduce the number of tablets per dose by half. In this study, patients with BPH were randomly assigned to either Eviprostat group (6 tabs/day) or EVI-F group (3 tabs/day) using the envelope method.

The clinical efficacy of these two drugs were evaluated by the International Prostate Symptom Score (IPSS) and QOL score at the end of the treatment period, and their safety was evaluated by the incidence of side effects.

Based on the clinical study guidelines for dysuria, the change in the IPSS total score and QOL score were comparable to the previously reported data for other treatment agents for BPH, and these indices showed gradual improvement with the treatment period.

Both treatments were well tolerated.

The clinical usefulness of the monotherapy with EVI-F tablet or Eviprostat tablet was reasonably demonstrated in this study. Furthermore, both treatments reduced nocturia, which has an impact on the QOL of patients with BPH.

PMID:

18634442